Author name: Claritas Rx

In an exciting development for the biopharma industry, Sanofi, OpenAI, and Formation Bio have announced a unique partnership aiming to develop AI-powered drug R&D software. This strategic alliance is a testament to the increasingly intertwined future of the technology and pharmaceutical sectors. This announcement follows closely on the heels of OpenAI’s other significant alliance with […]

Walgreens, a powerhouse in the retail and wholesale pharmaceutical sector, embarked on an unprecedented path with an impressive service upgrade – the incorporation of gene and cell therapies. This strategy extends Walgreens’ existing service portfolio and significantly advances healthcare. Let’s explore this groundbreaking endeavor and what it means for customers. Walgreens is expanding its specialty

The Food and Drug Administration (FDA) has recently been the center of attention in the biopharmaceutical world, pushing for a notable shift in the discourse surrounding biosimilars. The federal agency has openly campaigned for the abolition of ‘interchangeability‘ – a term it perceives as causing more confusion than clarity and adversely impacting the market penetration

The United States is currently experiencing an unsettling wave of drug shortages, as reported by the American Society of Health-System Pharmacists (ASHP). This ongoing crisis is putting the flexibility and robustness of our healthcare system to the test amid an unparalleled rise in medication shortages. According to the ASHP report, the first three months of

In the realm of healthcare, the patient journey stands as a fundamental framework, guiding the interaction between patients, healthcare providers, and the wider health ecosystem. But within the vast spectrum of patient care, not all journeys are equal. Some are marked by urgency, the relentless pursuit of health, and the stark realities of a life

As we step further into the fray and journey into the world of healthcare, one startling revelation makes itself known – cost-related medication non-adherence is a reality that 1 in 6 US patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD) have to deal with, according to a recent article published by The American Journal of

In the dynamic terrain of the biopharmaceutical industry, patient services have surfaced as a pivotal differentiator for manufacturers. With an increased emphasis on patient-centric care, pharma manufacturers are rethinking ways to extend beyond mere provision of medication. Today’s patients seek holistic support; they demand comprehensive service programs that guide them through the intricate healthcare labyrinth

The field of cell and gene therapy is rapidly transforming today’s treatment landscape for complicated cases like rare diseases. Simon Alfano, Alex Gorham, Alberto Loche, and Pablo Salazar report that biopharmaceutical companies are working diligently to develop new, life-saving products, with over 50 new cell and gene therapies launched in 2024, in an article on McKinsey & Company.